Last updated: February 16, 2026
Product Overview
NDC 68180-0944 corresponds to REGEN-COV (casirivimab and imdevimab), an authorized monoclonal antibody cocktail for COVID-19 treatment. It has received Emergency Use Authorization (EUA) from the FDA for outpatient use in high-risk populations.
Market Size and Demand Drivers
Demand remains influenced by COVID-19 variants, vaccine coverage, and hospitalization rates. Despite waning pandemic conditions, the product retains a niche for high-risk outpatient treatment. Key factors affecting demand include:
- Vaccination rates: Increasing vaccine uptake reduces severe cases, limiting the population for treatment.
- Variant emergence: Omicron and subvariants' susceptibility impacts efficacy and utilization.
- Hospitalization trends: Fluctuate based on infection waves, affecting distribution channels.
The COVID-19 therapeutics market, including monoclonal antibodies, experienced peaks in 2021 with global sales reaching approximately $10 billion. As of 2023, annual sales for monoclonal antibodies for COVID-19 are estimated at $2-4 billion, with REGEN-COV holding a substantial share in early 2022 but declining with new treatments and variant resistance.
Competitive Landscape
Main competitors include other monoclonal antibodies such as sotrovimab and bebtelovimab, which have different profiles against emerging variants. The market also sees competition from antiviral drugs like Paxlovid and molnupiravir.
Key competitors' market shares vary but REGEN-COV's utilization has decreased by approximately 50-60% since mid-2022. Its residual demand mainly stems from high-risk immunocompromised patients and areas with resistant variants.
Pricing Analysis
- Initial Pricing:
The wholesale acquisition cost (WAC) for REGEN-COV was approximately $2,100 per dose in early 2021.
- Reimbursement and Actual Prices:
Medicare and commercial insurers typically reimburse at lower rates, around $1,200–$1,500 per dose after negotiations and discounts.
- Public Procurement:
The U.S. government purchased doses at approximately $300–$400 during the peak of distribution effort.
Price Trends and Projections
Pricing is expected to decline further due to:
- Disease prevalence decline: Lower demand reduces pricing leverage.
- Increased competition: Alternatives with broader variant coverage or oral regimens reduce REGEN-COV's market power.
- Manufacturing scale: Larger-scale production may marginally lower costs, but this effect remains moderate.
Projected Pricing Range (2023-2025):
| Year |
Average Price per Dose |
Notes |
| 2023 |
$800–$1,200 |
Price reductions continue as demand declines. |
| 2024 |
$600–$900 |
Further competition and variant resistance influence prices. |
| 2025 |
$500–$700 |
Expected stabilization at lower levels. |
Regulatory and Policy Effects
Changes in EUA status or full FDA approval could impact pricing. An EUA withdrawal would sharply curtail demand and prices. Conversely, expanded labeling or use in new indications could temporarily stabilize or increase prices.
Key Challenges and Considerations
- Variants' resistance to monoclonal antibodies necessitates ongoing development.
- Policy shifts favoring oral antivirals could phase out monoclonal antibody reliance.
- Contractual agreements with government and insurers influence real-world pricing and revenue streams.
Summary
REGEN-COV's market is contracting, driven by evolving viral resistance, vaccination coverage, and competitive treatments. Price projections suggest a decline from roughly $1,000–$1,200 per dose in 2023 to around $500–$700 by 2025. Its future depends on regulatory decisions, variant landscape, and relative positioning against oral therapies.
Key Takeaways
- The monoclonal antibody market for COVID-19, led by REGEN-COV, faces a declining demand trend.
- Current prices range between $800 and $1,200 per dose, with further reductions expected.
- Competition and virus evolution are primary determinants of market size and prices.
- Policy and regulatory status will significantly influence future sales and pricing.
- Pricing will likely stabilize at lower levels by 2025 due to market saturation and treatment shifts.
FAQs
-
What is the main driver of REGEN-COV’s declining market share?
The emergence of resistant variants and increased use of oral antivirals reduce demand for monoclonal antibody treatments like REGEN-COV.
-
How do prices for REGEN-COV compare across different payers?
Wholesale prices are around $2,100 per dose, but actual reimbursements vary, averaging $1,200–$1,500 for insurers, while government procurement rates are lower, around $300–$400.
-
What factors could stabilize or increase REGEN-COV pricing?
Regulatory approval expansion, new indication approvals, or a resurgence of resistant variants could temporarily halt price declines.
-
Will REGEN-COV remain commercially viable in the next two years?
Its future viability depends on viral evolution, competition from oral antivirals, and regulatory decisions, implying a likelihood of diminishing use.
-
Are there significant regional differences in REGEN-COV demand?
Yes, demand remains higher in regions with slower vaccine rollout, high immunocompromised populations, or where variants resist other treatments.
References
[1] IQVIA, "COVID-19 Therapeutics Market Report," 2023.
[2] U.S. Food and Drug Administration, EUA documentation for REGEN-COV, 2021.
[3] Centers for Disease Control and Prevention, COVID-19 vaccination and variant prevalence data, 2023.
[4] Drug pricing databases and manufacturer disclosures, 2023.
